Rare side effects study of Brigatinib
In 2017, FDA approved a next generation ALK inhibitor Brigatinib (Brand name ALUNBRIG, Ariad) as a second-line therapy after the treatment from crizotinib (Brand name XALHORI, Pfizer) for ALK+ NSLC (non-small lung cancer).
Brigatinib tablets are generally available in 30mg , 90mg and 180mg.
Source: https://shorturl.at/izMW6
#Brigatinib #RareSideEffects #SideEffectStudy #medicalresearch #rarediseases #HealthCare #Pharmacology #medicalscience #DrugSafety #BrigatinibStudy #HealthScience
In 2017, FDA approved a next generation ALK inhibitor Brigatinib (Brand name ALUNBRIG, Ariad) as a second-line therapy after the treatment from crizotinib (Brand name XALHORI, Pfizer) for ALK+ NSLC (non-small lung cancer).
Brigatinib tablets are generally available in 30mg , 90mg and 180mg.
Source: https://shorturl.at/izMW6
#Brigatinib #RareSideEffects #SideEffectStudy #medicalresearch #rarediseases #HealthCare #Pharmacology #medicalscience #DrugSafety #BrigatinibStudy #HealthScience
02:36 AM - Mar 07, 2024
Only people mentioned by 911GlobalMeds in this post can reply